{"filing":{"accession_number":"0001193125-26-424695","cik":"0001479615","ticker":"SLNCF","company_name":"Silence Therapeutics plc","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-18","primary_document":"d172259d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526424695/d172259d8k.htm"},"events":[{"id":35962,"run_id":33151,"accession_number":"0001193125-26-424695","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Silence Therapeutics entered into a definitive agreement with Merck KGaA on October 18, 2026, to be acquired for $20.00 per ADS ($6.6667 per ordinary share) in an all-cash transaction valued at approximately $1.3 billion in equity value, representing a 130% premium to the prior closing price. The transaction is subject to shareholder approval, High Court sanction, and regulatory approvals, with expected closing in Q1 2027.","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40202,"accession_number":"0001193125-26-424695","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Silence Therapeutics entered into a definitive transaction agreement with Merck KGaA on October 18, 2026, whereby Merck will acquire all outstanding shares of Silence for $20.00 per ADS ($6.6667 per ordinary share) in an all-cash transaction valued at approximately $1.3 billion in equity value. This is a material acquisition requiring shareholder approval, High Court sanction, and regulatory approvals, with expected closing in Q1 2027. The transaction represents a 130% premium to the closing price on October 16, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:06:47.598354+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40203,"accession_number":"0001193125-26-424695","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Silence Therapeutics announced entry into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash transaction valued at approximately $1.3 billion equity value ($20.00 per ADS, representing a 130% premium). This is a material acquisition/change of control transaction subject to shareholder approval and regulatory conditions, with expected closing in Q1 2027. The press release explicitly describes this as a \"definitive agreement\" for acquisition, which is the core M\u0026A activity disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:06:47.598354+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40202,"accession_number":"0001193125-26-424695","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Silence Therapeutics entered into a definitive transaction agreement with Merck KGaA on October 18, 2026, whereby Merck will acquire all outstanding shares of Silence for $20.00 per ADS ($6.6667 per ordinary share) in an all-cash transaction valued at approximately $1.3 billion in equity value. This is a material acquisition requiring shareholder approval, High Court sanction, and regulatory approvals, with expected closing in Q1 2027. The transaction represents a 130% premium to the closing price on October 16, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:06:47.598354+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-10-19"},{"id":40203,"accession_number":"0001193125-26-424695","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Silence Therapeutics announced entry into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash transaction valued at approximately $1.3 billion equity value ($20.00 per ADS, representing a 130% premium). This is a material acquisition/change of control transaction subject to shareholder approval and regulatory conditions, with expected closing in Q1 2027. The press release explicitly describes this as a \"definitive agreement\" for acquisition, which is the core M\u0026A activity disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:06:47.598354+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-10-19"}]}